When people search for "BMP-7 what is it", they usually mean bone morphogenetic protein 7, also known as OP-1 (osteogenic protein-1). This is not a short peptide but a full secreted protein of the TGF-β family. Below is a measured overview: what it is, how it works, what has been studied with it, and why the product built on it, which was genuinely available in the clinic at one point, disappeared from there.

Disclaimer. BMP-7 from Longeva is a research substance (reagent) for laboratory use only (research-use-only). It is not a medicine and not a dietary supplement; the material is not intended for the diagnosis, treatment or prevention of disease in humans or animals.

What BMP-7 is

BMP-7 (bone morphogenetic protein 7) belongs to the transforming growth factor beta (TGF-β) superfamily. Its second common name, OP-1 (osteogenic protein-1), comes from the work in which the protein was identified precisely by its ability to induce bone formation.

Structurally it is not a peptide but a homodimer: two identical subunits joined by a disulfide bridge, each with the cystine-knot fold characteristic of the whole family. The molecule is glycosylated. Dimerisation matters here: a single monomer is inactive, because the receptors have to be cross-linked in pairs.

Technical reference points for anyone working with the reagent:

  • Class: secreted signalling protein, TGF-β superfamily
  • Synonyms: OP-1, osteogenic protein-1; the recombinant form has the international name eptotermin alfa
  • Gene: BMP7
  • Supply form: recombinant protein, lyophilised

Mechanism of action

BMP-7 binds BMP receptors of types I and II, which are serine-threonine kinases. The type II receptor phosphorylates the type I receptor, which in turn phosphorylates the intracellular proteins SMAD1/5/8; together with SMAD4 these move into the nucleus and switch on transcription of osteogenic genes, in particular RUNX2. That is the canonical pathway.

The second side of the mechanism is the more interesting one. BMP-7 is described as a natural counterweight to TGF-β1: TGF-β1 signals through SMAD2/3 and drives fibrogenesis and epithelial-to-mesenchymal transition, whereas BMP-7 acts in the opposite direction through SMAD1/5/8. It is this antifibrotic axis that made the protein a subject of research well beyond bone biology.

What the research shows

Bone. Historically the first and best-developed direction: recombinant BMP-7 was studied for the union of difficult nonunion fractures and in spinal surgery. Human data exist here, which is exactly why this direction has to be assessed separately from the rest.

Kidneys and fibrosis. In rodents BMP-7 reduced the severity of renal fibrosis in models of chronic injury by counteracting TGF-β1-dependent reprogramming of cells. The data are preclinical.

Brown adipose tissue. A separate line of work described the ability of BMP-7 to steer adipocyte precursors towards brown fat and to raise energy expenditure in mice. This is one of the reasons for the metabolic interest in the protein, and it is also preclinical.

Genetics. Mice lacking the BMP7 gene die shortly after birth with severe defects of the kidneys and eyes. This is not a subtle modifier but a gene critical for development.

Clinical history: why OP-1 disappeared

This is the part usually skipped in overviews of "research molecules". Recombinant BMP-7 really was available in clinical practice under the name OP-1: it was used in difficult cases of long-bone nonunion and in spinal surgery, and it got there through limited regulatory mechanisms rather than as an ordinary broadly registered drug.

The product was later wound down. The reasons were combined: ambiguous results compared with an autograft of the patient's own bone, which remains the standard, high cost, and commercial decisions by the manufacturer. So BMP-7 was not "banned as dangerous", but neither was it confirmed as an option superior to the existing standard of care.

For context: the related BMP-2 has its own, considerably louder history with separate safety questions in spinal surgery. These are different proteins, and carrying conclusions from one over to the other is not sound.

How reliable the evidence is

Two layers have to be kept clearly apart here. For bone, clinical data in humans exist, but they are ambiguous, and there is no product on the market now. For fibrosis, kidneys and metabolism, everything available is preclinical work: cell cultures and rodents. No clinical trials of BMP-7 have been run for those indications.

What this means in practice:

  • BMP-7 is a well-characterised research object with a clearly described mechanism and, unusually for this category, a real clinical history;
  • it is not a means of "restoring joints", "treating kidneys" or "burning fat" in humans;
  • categorical promises of that sort have no clinical grounding.

Handling notes

This is a protein, not a short peptide, and the requirements differ. Recombinant dimeric proteins are more sensitive to denaturation: losing the spatial structure means losing activity, even if the analytical mass formally "matches". The lyophilisate is kept frozen, repeated freeze-thaw cycles are avoided, reconstitution is done gently without vigorous shaking, and the prepared solution is not left at room temperature for long.

In brief: frequent questions

Is BMP-7 a peptide? No. It is a secreted glycosylated homodimeric protein of the TGF-β family, considerably larger and structurally more complex than short peptides such as KPV or BPC-157.

How does it differ from BMP-2? They are different proteins of the same family with different application profiles and different clinical histories. A shared name does not make them interchangeable.

Can it be used to "restore cartilage or kidneys"? No. Such claims rest on preclinical models, and there is no clinical confirmation for humans.

In what form is the reagent supplied? As a lyophilised recombinant protein, reconstituted immediately before laboratory use.

Summary

BMP-7 is interesting for exactly the reason most "fashionable" molecules are not: it has a clear described mechanism, a real clinical history, and an honest documented ending to that history. It remains a strong tool for laboratory research on osteogenesis and TGF-β-dependent fibrosis, and at the same time a clear illustration that a convincing mechanism on its own does not equal clinical benefit.

For batch specifications and the COA (Certificate of Analysis, a batch-specific lab certificate), see the BMP-7 page in the Longeva catalogue.

The main point once again. Longeva supplies BMP-7 for laboratory research only. It is not a medicine, not a supplement and not a treatment recommendation. A decision about any intervention in health is taken by a doctor on the basis of data, not on the basis of overviews found online.

Related: BMP-7 (OP-1): what the research showed in fibrosis and scarring.